(Q44212774)

30 November 2017

title

CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer (English)

1 reference

30 November 2017

1 reference

Nicole D Fleming

1

1 reference

30 November 2017

Ilana Cass

2

1 reference

30 November 2017

Christine S Walsh

3

1 reference

30 November 2017

Beth Y Karlan

4

1 reference

30 November 2017

Andrew J Li

5

1 reference

30 November 2017

language of work or name

English

0 references

publication date

5 February 2011

1 reference

30 November 2017

1 reference

30 November 2017

volume

121

1 reference

30 November 2017

issue

2

1 reference

30 November 2017

page(s)

249-252

1 reference

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

Critical evaluation of secondary cytoreduction in recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.014

10.1016/J.YGYNO.2011.01.014

7 January 2021

Identifiers

DOI

1 reference

30 November 2017

1 reference